Pending enough primary studies, we invite reviews on this topic to be conducted. Alternatively, we will endeavour to conduct our own review to fill this gap in the Library.

November 2021

Image: ©Coka – Fotolia – stock.adobe.com

The post Acupuncture appeared first on NeuRA Library.

Bipolar disorder is thought to be associated with a purinergic system dysfunction, particularly in the manic phases of the disorder. Moreover, depressive temperaments have been related to both high and low levels of uric acid. Allopurinol is used for the treatment of gout and hyperuricemia; it inhibits purine degradation and subsequently increases adenosine levels.

What is the evidence for adenosine modulators?

Moderate quality evidence suggests adjunctive allopurinol may improve mania symptoms in people with bipolar disorder, but not for those in a mixed mood state.

November 2021

Image: ©lyricsai – stock.adobe.com

The post Adenosine modulators appeared first on NeuRA Library.

Most antidepressants increase serotonin or noradrenaline, and are effective for the treatment of unipolar depression. However, as they may increase the risk of phase shifting from depression to mania in people with bipolar disorder, they are generally used only when the depressive phase is severe and shows poor response to mood stabilisers or antipsychotics.

What is the evidence on antidepressants for bipolar depression?

Moderate to high quality evidence suggests second generation antidepressants (with or without mood stabilisers), are a more effective long-term prophylactic treatment for relapse to depression than placebo (with or without mood stabilisers). Moderate to low quality evidence suggests no differences in relapse rates to depression or mania between antidepressants and mood stabilisers.

Moderate quality evidence suggests ~19% of people with bipolar depression taking antidepressants switch to mania. Switching rates are highest in people with a family history of affective disorders, previous suicide attempts, depression polarity of the index episode, lifetime psychotic features, and rapid- cycling course. Rates were lowest in people taking antidepressants with concurrent lithium.

November 2021

Image: ©alexlmx2016 – stock.adobe.com

The post All antidepressants appeared first on NeuRA Library.

Growing evidence suggests that inflammatory processes may contribute to the development of mental disorders. Pro-inflammatory cytokines interleukin (IL) 4, tumor necrosis factor alpha (TNF-a), soluble IL-2 receptor (sIL-2R), IL-1b, IL-6, soluble receptor of TNF-a type 1 (STNFR1), and C-reactive protein (CRP) have been shown to be elevated in people with bipolar disorder compared to healthy controls. This suggests a potential role for anti-inflammatory agents in the treatment of bipolar disorder. These agents primarily include non-steroidal anti-inflammatory agents (e.g., aspirin, celecoxib), but also omega-3 polyunsaturated fatty acids, N-acetylcysteine (a glutemate modulator) and pioglitazone (an antidiabetic) have some anti-inflammatory properties.

What is the evidence for anti-inflammatory medications?

Moderate to high quality evidence finds adjunctive omega-3 to be more effective than placebo for depression, but not for mania symptoms. There is good evidence of some benefit of adjunctive celecoxib over placebo for mania symptoms. Moderate quality evidence finds some benefit of adjunctive N-acetylcysteine over placebo for depression, with no differences in adverse events. The finding for depression was not consistently found across reviews due to slight differences in included studies. Moderate to low quality evidence finds no benefit of adjunctive aspirin for depression, and low quality evidence is unable to determine any benefits of pioglitazone.

November 2021

Image: ©Shane Maritch Photography – stock.adobe.com

The post Anti-inflammatories appeared first on NeuRA Library.

Peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonists such as pioglitazone are used to treat type 2 diabetes. In the context of comorbid diabetes and depressive disorders, studies have shown that pioglitazone also has antidepressant properties. This topic assesses the evidence for antidiabetic medications for the treatment of depression in people with bipolar disorder.

What is the evidence for antidiabetic medications?

Low quality evidence is unable to determine the benefits of pioglitazone for depression in people with bipolar disorder. Note that this result was due to only one small study of people with bipolar disorder. When the analysis also included people with major depression, the results significantly favoured pioglitazone for the treatment of depression.

November 2021

Image: ©ollaweila – stock.adobe.com

The post Antidiabetics appeared first on NeuRA Library.

The primary treatments for bipolar disorder are pharmacological, and often involve second generation antipsychotic drugs such as aripiprazole. Aripiprazole is is a partial agonist of dopamine D2 and serotonin 5-HT1A receptors and an antagonist of 5-HT2A receptors. It has a distinct receptor-binding profile compared to other second generation antipsychotic drugs.

What is the evidence for aripiprazole as a treatment for bipolar disorder?

Mania and psychotic symptoms

Moderate quality evidence suggests a small effect of greater improvement with aripiprazole than with placebo. The effect for mania is large in pediatric patients. There were no differences in mania symptoms between aripiprazole and other medications, however, there were large effects of more switching to mania with aripiprazole than with quetiapine or ziprasidone.

Depressive symptoms

Moderate to high quality evidence suggests no significant differences between aripiprazole and placebo for depression. Moderate quality evidence suggests less improvement in depression, less response to treatment, and less likelihood of remission with aripiprazole than with lurasidone.

Overall symptoms and prevention of relapse

Moderate quality evidence suggests greater overall improvement in symptoms with aripiprazole than with haloperidol or lithium. There were medium-sized effects of fewer relapses with aripiprazole + valproate or aripiprazole + lamotrigine than with placebo. There were also fewer relapses with aripiprazole + valproate than with paliperidone or imipramine. Also see the topics on relapse prevention and polypharmacy.

Side effects

Moderate quality evidence suggests more high-density lipoprotein, sedation, extrapyramidal symptoms, constipation, nausea, vomiting, anxiety, salivation, fatigue, insomnia, and pain in the extremities with aripiprazole than with placebo. However, there was less hyperprolactinemia, less elevated fasting glucose, less increased appetite, and less total cholesterol with aripiprazole.

November 2021

Image: ©Darwin Brandis – stock.adobe.com

The post Aripiprazole appeared first on NeuRA Library.

The treatment of bipolar disorder is complex due to the presence of varying configurations of symptoms in patients. The primary treatments for bipolar disorder are pharmacological, and often involve second generation antipsychotic drugs, such as asenapine. Based on its high affinity for seratonin receptors, asenapine has been proposed as a treatment for bipolar disorder.

What is the evidence for asenapine as a treatment for bipolar disorder?

Moderate to high quality evidence suggests small to medium-sized effects of greater improvement in mania and depression symptoms with asenapine monotherapy than with placebo. However, there were more extrapyramidal side effects, somnolence, dizziness, sedation, blood glucose, and weight gain with asenapine.

Moderate to high quality evidence suggests no differences between asenapine monotherapy and olanzapine monotherapy for mania symptoms. There was no analysis of depression symptoms. There was more dizziness and parkinsonism with asenapine, and more weight gain and higher prolactin levels with olanzapine.

Also see the topic on relapse prevention.

November 2021

Image: ©cassis – stock.adobe.com

The post Asenapine appeared first on NeuRA Library.

Benzodiazepines are minor tranquillisers that may be implemented as an adjunct to other medications in order to treat acute symptoms, such as agitation, aggression, irritability, and anxiety. They may also be used to treat side effects of antipsychotic medications such as movement disorders, including tardive dyskinesia. However, benzodiazepines are associated with their own side effects and are associated with well-established patterns of tolerance and dependence, so they are prescribed with caution.

What is the evidence for benzodiazepines?

Moderate to low quality evidence suggests the benzodiazepine lorazepam is less effective than intramuscular antipsychotics olanzapine and aripiprazole for reducing agitation in people with bipolar disorder.

November 2021

Image: ©Cappi Thompson – stock.adobe.com

The post Benzodiazepines appeared first on NeuRA Library.

Exposure to blue light affects circadian rhythm, and night time exposure can lead to insomnia via dysregulation of melatonin. Blue light blocking glasses have been found to prevent light-induced suppression of melatonin release. The glasses are worn continuously for two to three hours before turning the lights off to sleep with the aim of improving sleep. It is thought this may also improve mood in people with bipolar disorder. 

What is the evidence for blue light blocking glasses?

Moderate to low quality evidence suggests blue light blocking glasses may improve mania symptoms and sleep in people with bipolar disorder, although sample sizes are small. More research is needed.

Also see the topic on melatonin for the symptoms of bipolar disorder.

November 2021

Image: ©Alina Rosanova – stock.adobe.com

The post Blue light blocking glasses appeared first on NeuRA Library.

Bright light therapy, also called phototherapy, involves the use of a bright artificial light to improve depressive mood. It has long been used in psychiatric practice, usually for the treatment of seasonal affective disorder. The mechanism by which bright light therapy regulates mood is unclear. It has been suggested to have modulating effects on serotonin and melatonin and on the synchronisation of circadian rhythms, which is why it is often accompanied by sleep deprivation. This topic assesses the use of bright light therapy for depressive symptoms of bipolar disorder.

What is the evidence for bright light therapy?

Moderate to high quality evidence finds a medium-sized improvement in depression symptoms with bright light therapy compared to placebo. There was no increased risk of shifting to a manic state with bright light therapy.

Moderate quality evidence finds greater improvements in depression symptoms in studies using <10 hours compared to >10 hours of bright light therapy, in studies using morning plus night exposure compared to morning exposure only, and in studies with adjunctive sleep deprivation and/or lithium. There were no differences in studies with or without other psychotropic medications, in studies using colour temperature < vs. >4500k, in studies using light intensity < vs. >5000lux, or in studies using white or green light thera

November 2021

Image: ©Alex Lypa – stock.adobe.com

The post Bright light therapy appeared first on NeuRA Library.